TP53 and B-cell chronic lymphocytic leukemia: To date, the key decision making biomarkers in CLL are TP53 defects—deletion of the 17p13 locus and/or mutation(s) within the TP53 gene—which are associated with resistance to chemoimmunotherapy and poor clinical outcome [5,70,71].